DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
DFV890：一种新型口服NLRP3抑制剂，已在早期2a期随机临床试验中对COVID-19肺炎合并呼吸功能障碍患者进行了测试。
期刊:Infection
影响因子:3.6
doi:10.1007/s15010-022-01904-w
Madurka, Ildiko; Vishnevsky, Alexander; Soriano, Joan B; Gans, Stephanus J; Ore, Danilo Joel Salazar; Rendon, Adrian; Ulrik, Charlotte S; Bhatnagar, Sushma; Krishnamurthy, Srikanth; Mc Harry, Kirsten; Welte, Tobias; Fernandez, Alberto A; Mehes, Beata; Meiser, Karin; Gatlik, Ewa; Sommer, Ulrike; Junge, Guido; Rezende, Ederlon
